Smith, Gambrell & Russell, LLP
Treating learning deficits with inhibitors of Hmg CoA reductase
The disclosure provides methods of treating cognitive disorders by administering a HMG CoA reductase inhibitor. Cognitive deficits treatable with the inhibitor compound include those associated with Angelman Syndrome, Neurofibromatosis-1, certain forms of X-linked mental retardation, tuberous sclerosis, Down Syndrome, autism, and attention deficit/hyperactivity disorder.
Regents of the University of Carolina
A A A
A61K A61P A61P
inventional inventional inventional
Weldong Alcino Yijun Steven A.
Li Silva Cui Kushner